Lymecycline
- Generic Name
- Lymecycline
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H38N4O10
- CAS Number
- 992-21-2
- Unique Ingredient Identifier
- 7D6EM3S13P
- Background
Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.
- Indication
Lymecycline is used for the treatment of acne in addition to other susceptible infections; propionibacterium is often the cause of acne. Some of the infections that can be treated with lymecycline include upper respiratory tract infections, urinary tract infections, bronchitis, chlamydial infections, and rickettsial infections.
- Associated Conditions
- Acne Vulgaris, Susceptible Bacterial Infections
- Associated Therapies
- -
Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Ostergotland County Council, Sweden
- Target Recruit Count
- 160
- Registration Number
- NCT01661985
- Locations
- 🇸🇪
R&D dept of Local Health Care, Östergötland county council, Linköping, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.